HansBiomed Corporation (042520) — Capital Reinvestment Ratio

Latest as of September 2025: 0.37x

HansBiomed Corporation (042520) has a Capital Reinvestment Ratio of 0.37x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩1.21 Billion) in capital expenditures (₩448.85 Million). Check tangible equity quality of HansBiomed Corporation to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.37x
Capex / Operating Cash Flow

Operating Cash Flow

₩1.21 Billion
KRW

Capital Expenditures

₩448.85 Million
KRW

Data as of

Sep 2025
Most recent filing

HansBiomed Corporation Capital Reinvestment Ratio (2012–2025)

This chart tracks HansBiomed Corporation's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of HansBiomed Corporation.

Annual Capital Reinvestment Ratio for HansBiomed Corporation (2012–2025)

Year-by-year Capital Reinvestment Ratio for HansBiomed Corporation from 2012 to 2025. See 042520 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2025 5.52x ₩318.34 Million ₩1.76 Billion ▲ +243.2%
2024 1.61x ₩1.76 Billion ₩2.83 Billion ▲ +31.3%
2020 1.23x ₩5.75 Billion ₩7.05 Billion ▼ -39.3%
2019 2.02x ₩7.71 Billion ₩15.56 Billion ▲ +368.7%
2018 0.43x ₩5.20 Billion ₩2.24 Billion ▼ -81.5%
2017 2.33x ₩5.60 Billion ₩13.05 Billion ▲ +33.1%
2015 1.75x ₩3.47 Billion ₩6.07 Billion ▼ -70.9%
2014 6.01x ₩2.06 Billion ₩12.39 Billion ▲ +92.3%
2013 3.13x ₩2.33 Billion ₩7.29 Billion ▲ +1750.5%
2012 0.17x ₩1.50 Billion ₩253.56 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow